| HOME >> BIOLOGY >> TECHNOLOGY |
- Company Appoints Charles Rowland to Chief Financial Officer -
EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has appointed its new chief financial officer, and strengthened its leadership in human resources, clinical development and medical affairs. Charles Rowland has joined the company as vice president and chief financial officer; Thomas Macnamara has been promoted to the position of vice president, human resources; Steven Gelone, Pharm. D. has transitioned to the role of vice president, clinical development programs; and Glenn Tillotson, Ph. D. has joined the company as head of medical affairs.
"It is essential that we have strong leaders throughout our organization that can optimize the development of ViroPharma, particularly as our business expands and we grow the organization globally," commented Vincent Milano, ViroPharma's president and chief executive officer. "These enhancements augment our already strong team. Charlie, Steve, Tom and Glenn have the right experience, integrity and drive to help direct ViroPharma into its next phase of growth and success."
Charles A. Rowland Jr., CPA, MBA, has 28 years of diversified
experience across a broad field of financial areas. As vice president and
chief financial officer, Mr. Rowland will be responsible for all areas of
finance and accounting, including financial reporting, tax, treasury, and
strategic financial planning. Most recently, he was the executive vice
president and chief financial officer for Endo Pharmaceuticals, as well
serving for a period as co-interim chief executive officer. At Endo, Mr.
Rowland drove the strategic planning process through two successive chief
executive officers. He a
'/>"/>
| SOURCE ViroPharma Incorporated Copyright©2008 PR Newswire. All rights reserved |